Wikisage, the free encyclopedia of the second generation, is digital heritage
Aspirin: Difference between revisions
Jump to navigation
Jump to search
m (→ATC) |
m (→Kawasaki) |
||
| Line 3: | Line 3: | ||
A recommendation of AAs-clopidogrel to maintain the patency of the stent following coronary intervention. Clopidogrel is a P2Y12 inhibig platelet agent; the combination AAs Ticagrelor wasn´t better than clopidogrel+aspirin | A recommendation of AAs-clopidogrel to maintain the patency of the stent following coronary intervention. Clopidogrel is a P2Y12 inhibig platelet agent; the combination AAs Ticagrelor wasn´t better than clopidogrel+aspirin | ||
<ref>https://www.mdpi.com/2077-0383/8/1/104/htm Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting]</ref> | <ref>https://www.mdpi.com/2077-0383/8/1/104/htm Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting]</ref> | ||
[[File:Kawasaki_tongue_1.jpg|thumb]] | |||
==Kawasaki== | ==Kawasaki== | ||
Revision as of 12:29, 24 January 2019
Aspirin is an NSAID [1] A recommendation of AAs-clopidogrel to maintain the patency of the stent following coronary intervention. Clopidogrel is a P2Y12 inhibig platelet agent; the combination AAs Ticagrelor wasn´t better than clopidogrel+aspirin [2]
Kawasaki
Protocols recommend AAs and intravenous immunoglubin; however many cases have be shown to be refractory to this treatment [3]
Hutchinson Gliford Progeria
Low dosis Aspirin 2-3 mg/Kg body weight is recommended for prevention of cardiovascular and stroke complications [4]
ATC
Salicylic acid and derivates
- Acetylsalicylic acid (INN)
Links
- ↑ https://karmel.miraheze.org/wiki/PenaRC2/profilaxis_AAS
- ↑ https://www.mdpi.com/2077-0383/8/1/104/htm Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting]
- ↑ A case report of refractory kawasaki disease
- ↑ Hutchinson-Gilford Progeria Syndrome
